{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:48:23Z","timestamp":1784166503022,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Royal Library, Copenhagen University Library"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Little is known about treatment of osteoporosis with denosumab (Prolia\u00ae) in patients with decreased kidney function. The aim of this retrospective case report study was to investigate effects and side-effects of such treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Since 2012, 75 patients with osteoporosis and decreased kidney function had been treated with denosumab (Prolia\u00ae) in the osteoporosis outpatient clinic of the department of endocrinology, Bispebjerg Hospital, University of Copenhagen, Denmark, and data were retrospectively collected from the patient records of these patients in 2021.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At baseline, the mean estimated glomerular filtration rate (eGFR) was 34\u00a0mL\/min (range 9\u201350) and the median age was 85\u00a0years (range 45\u2013103). 95% of the patients had had low-energy fractures, and the bone mineral density <jats:italic>T<\/jats:italic> score of the hips was on average\u2009\u2212\u20092.7. All, but one, patients had normal\/high parathyroid hormone (PTH) levels.<\/jats:p>\n                <jats:p>The mean duration of the treatment with denosumab at the follow-up was 5.3\u00a0years (range 1.5\u201310). There was an annual increase of 12% and of 7% in the <jats:italic>T<\/jats:italic> score of in the lumbar spine and hip, respectively, compared to the <jats:italic>T<\/jats:italic>-scores prior to the denosumab treatment. 20% had a new fracture during the follow-up. 21% had biochemical hypocalcemia following denosumab injection, 7% developed symptoms of hypocalcemia, whereas 4% needed to be hospitalized acutely.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Treatment with denosumab of osteoporosis in patients with decreased kidney function (eGFR 9\u201350\u00a0mL\/min), with normal\/high PTH, seems in general to be well tolerated, with improvement of bone and decreased risk of new fractures.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11657-023-01306-x","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T22:01:31Z","timestamp":1690408891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of osteoporosis with denosumab in patients with decreased kidney function"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-9532","authenticated-orcid":false,"given":"Ole Lander","family":"Svendsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"1306_CR1","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s00198-022-06462-3","volume":"33","author":"M Abdalbary","year":"2022","unstructured":"Abdalbary M, Sobh M, Elnagar S et al (2022) Management of osteoporosis in patients with chronic kidney disease. Osteoporos Int 33:2259\u20132274","journal-title":"Osteoporos Int"},{"key":"1306_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-027735-9","author":"G Hampson","year":"2021","unstructured":"Hampson G, Elder GJ, Cohen-Solal M, Abrahamsen B (2021) A review and perspective on the assessment, management, and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. Endocrine. https:\/\/doi.org\/10.1007\/s12020-021-027735-9","journal-title":"Endocrine"},{"key":"1306_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.7326\/M16-2752","volume":"166","author":"LM Wilson","year":"2017","unstructured":"Wilson LM, Rebholz CM, Jirru E et al (2017) Benefits and harms of osteoporosis medications in patients with chronic kidney disease. Ann Intern Med 166:649\u2013658","journal-title":"Ann Intern Med"},{"key":"1306_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","volume":"36","author":"P Evenepoel","year":"2020","unstructured":"Evenepoel P, Cunningham J, Rerrari S et al (2020) European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4\u2013G5D. Nephrol Dial Transplant 36:42\u201359","journal-title":"Nephrol Dial Transplant"},{"key":"1306_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","volume":"106","author":"A Broadwell","year":"2021","unstructured":"Broadwell A, Chines A, Ebeling R et al (2021) Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106:397\u2013409","journal-title":"J Clin Endocrinol Metab"},{"key":"1306_CR6","unstructured":"Prolia. Summary of product characteristics. EMA (https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/prolia-epar-product-information_en.pdf) assessed March 22, 2023"},{"key":"1306_CR7","doi-asserted-by":"crossref","unstructured":"Tsourdi E, Zillikens C, Meier S et al (2021) Fracture risk and management of discontinuation of denosumab therapy. A systematic review and position statement by ECTS. J Clin Endocrinol Metab\u00a0106:264\u2013281","DOI":"10.1210\/clinem\/dgaa756"},{"key":"1306_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block G, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u00b4s changed and why it matters. Kidney Int 92:26\u201336","journal-title":"Kidney Int"},{"key":"1306_CR9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N (2021) Cardiovascular disease in chronic kidney disease. Circulation 143:1157\u20131172","journal-title":"Circulation"},{"key":"1306_CR10","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.3676","volume":"34","author":"K Iseri","year":"2019","unstructured":"Iseri K,\u00a0Watanabe M, Yoshikawa H et al\u00a0(2019) Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial. JBMR 34:1014\u20131024","journal-title":"JBMR"},{"key":"1306_CR11","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1038\/s41598-020-59143-8","volume":"10","author":"K Kunizawa","year":"2020","unstructured":"Kunizawa K, Hiramatsu R, Hoshino J et al (2020) Denosumab for dialysis patients with osteoporosis: a cohort study. Nat Sci Rep 10:2496. https:\/\/doi.org\/10.1038\/s41598-020-59143-8","journal-title":"Nat Sci Rep"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-023-01306-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-023-01306-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-023-01306-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:35:07Z","timestamp":1704375307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-023-01306-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1007\/s11657-023-01306-x","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"27 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For retrospective studies like this, no formal consent is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"104"}}